A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

OBJECTIVE: To assess the safety, tolerability, biological activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS: Patients with SELENA-SLEDAI score≥4 (N=449) were randomly assigned to belimumab (1, 4,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Wallace, Daniel J., Stohl, William, Furie, Richard A., Lisse, Jeffrey R., McKay, James D., Merrill, Joan T., Petri, Michelle A., Ginzler, Ellen M., Chatham, W. Winn, McCune, W. Joseph, Fernandez, Vivian, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2758229/
https://ncbi.nlm.nih.gov/pubmed/19714604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24699
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki